Aluminum Is Intricately Associated with the Neuropathology of Familial Alzheimer’s Disease

April 9, 2021 - Keele, UK – A new study published in the Journal of Alzheimer’s Disease Reports continues to support a growing body of evidence that aluminum contributes to the pathogenesis of Alzheimer’s disease (AD). Researchers found aluminum co-located with phosphorylated tau protein, which is an early initiator of AD. This study builds upon two earlier published studies (including Mold et al., 2020, Journal of Alzheimer’s Disease) from the same group. More...

April 9, 2021

Dementia and COVID: What Families and Physicians Should Know

In people with dementia, delirium during COVID-19 is more common but deaths from COVID-19 are not disproportionately higher, finds new study

April 5, 2021 - New York, NY, USA – Early in the pandemic, neurologists expressed concern that COVID-19 patients with dementia may be at higher risk for complications and mortality. But those fears have not been realized, according to a new study of patients who were hospitalized with COVID-19 during the first wave of the pandemic in New York City. The study, led by James Noble, MD, MS, associate professor of neurology at Columbia University Vagelos College of Physicians and Surgeons and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, and Amro Harb, a Vagelos medical student, has been published online in the Journal of Alzheimer’s Disease. More...

April 5, 2021

IOS Press Labs Goes Live

An invitation to visit a new virtual space that showcases innovative and technical achievements of IOS Press and the wider scholarly publishing community and join the conversation

April 7, 2021 - Amsterdam, NL – IOS Press, an international publisher providing content and services for scientific, technical, and medical (STM) communities, is proud to announce the launch of the new IOS Press Labs website. Labs is a virtual space where possibilities can be explored and experiences shared – from the latest technological advancements impacting knowledge dissemination and innovative content developments, to intelligent tools, participation in pioneering scholarly information industry initiatives, and provision of insights into trends in the publishing ecosystem. More...

April 7, 2021

New Study Expands Evaluation of Gene Therapy for Spinal Muscular Atrophy

Treatment with onasemnogene abeparvovec in a broader group of patients than clinical trials is associated with an immune response that needs careful monitoring, however there were no long-term side effects, report scientists in the Journal of Neuromuscular Diseases

April 6, 2021 - Amsterdam, NL – The rarity of spinal muscular atrophy (SMA) means that promising new treatments may be tested in only a limited spectrum of patients before approval. Investigators evaluated a newly approved drug, onasemnogene abeparvovec, in a broader spectrum of patients in order to obtain expanded data on its side effects profile. They report in the Journal of Neuromuscular Diseases that the drug is associated with an immune response against the adeno-associated viral vector and needs careful monitoring, but showed no long-term adverse effects. More...

April 6, 2021